Corvus Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.About CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.
CEORichard A. Miller
CEORichard A. Miller
Employees31
Employees31
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2014
Founded2014
Employees31
Employees31
CRVS Key Statistics
Market cap634.80M
Market cap634.80M
Price-Earnings ratio-15.87
Price-Earnings ratio-15.87
Dividend yield—
Dividend yield—
Average volume1.23M
Average volume1.23M
High today$8.92
High today$8.92
Low today$8.31
Low today$8.31
Open price$8.61
Open price$8.61
Volume1.20M
Volume1.20M
52 Week high$9.60
52 Week high$9.60
52 Week low$2.54
52 Week low$2.54
Stock Snapshot
The current Corvus Pharmaceuticals(CRVS) stock price is $8.60, with a market capitalization of 634.8M. The stock trades at a price-to-earnings (P/E) ratio of -15.87.
On 2025-12-11, Corvus Pharmaceuticals(CRVS) stock moved within a range of $8.31 to $8.92. With shares now at $8.60, the stock is trading +3.5% above its intraday low and -3.6% below the session's peak.
Trading activity shows a volume of 1.2M, compared to an average daily volume of 1.23M.
The stock's 52-week range extends from a low of $2.54 to a high of $9.60.
The stock's 52-week range extends from a low of $2.54 to a high of $9.60.
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CRVS. This list is generated using Robinhood data, and it’s not a recommendation.